Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 105

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 105
---
306 |   |     |      |       - |   |
| Other research and development expenses                                                                      |     |              |      (662 | ) |     |      |    (806 | ) |
| General and administrative expenses                                                                          |     |              |      (712 | ) |     |      |  (1,125 | ) |
| Operating (profit) loss                                                                                      |     |              |       932 |   |     |      |  (1,931 | ) |
| Financial income (expense), net:                                                                             |     |              |           |   |     |      |         |   |
| Changes in fair value of convertible notes                                                                   |     |              |     3,483 |   |     |      |  (2,019 | ) |
| Changes in fair value of warrant liability                                                                   |     |              |       463 |   |     |      |      62 |   |
| Other financing income (expense), net                                                                        |     |              |       (77 | ) |     |      |    (244 | ) |
| Net income (loss) and comprehensive income (loss)                                                            |     |              |     4,801 |   |     |      |  (4,132 | ) |
| Basic and diluted net income (loss) per share                                                                |     |              |      1.72 |   |     |      |  (24.09 | ) |
| Weighted average number of ordinary shares used in computing basic and diluted net income / (loss) per share |     |              | 2,765,850 |   |     |      | 173,508 |   |

<div align='center'>64</div>

Year Ended December 31, 2024 Compared to Year Ended December 31, 2023

Research and development expenses

Research and development
expenses decreased by approximately $2,450 thousand or 303.9%, to approximately income of $1,644 thousand for the year ended December
31, 2024, compared to $806 thousand for the year ended December 31, 2023. The decrease resulted mainly from the Horizon 2020 Grant, and
from a decrease in subcontractors’ expenses due to lower research and development activity during 2024 partly offset by an increase
in expenses related to CSL Settlement, which was recorded during 2024.

General and administrative expenses

General and administrative
expenses decreased by approximately $413 thousand, or 36.7%,